Adlai Nortye Ltd ADR (ANL)
Adlai Nortye Ltd ADR (NASDAQ: ANL) is a depositary receipt tied to Adlai Nortye Ltd., a clinical-stage biotechnology company focused on researching and developing pharmaceutical products. The company’s lead candidate, AN2025, is a pan-phosphoinositide 3-kinase inhibitor being evaluated in Phase III trials for recurrent or metastatic head and neck squamous cell carcinoma. Adlai Nortye is also advancing AN0025, a small-molecule prostaglandin E receptor 4 antagonist in Phase Ib studies across several cancer indications, and AN4005, an oral small-molecule PD-L1 inhibitor in Phase I trials. Its preclinical pipeline includes AN8025, a multifunctional antibody candidate, and AN9025, an oral pan-KRAS inhibitor. Founded in 2004, the company is based in Grand Cayman, the Cayman Islands.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ANL
|
$6.11
|
-49.6% Downside
|
Overvalued
|
$28.60
|
136.0% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-13.7x
|
-58.3x
|
97.0x
|
479.2 M
|
502.6 M
|
5.2%
|
46.0%
|
-16.0
|
—
|
94.7%
|
